Literature DB >> 12627259

Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.

John Kouvaris1, Vassilis Kouloulias, Elias Malas, Christos Antypas, John Kokakis, Spyros Michopoulos, George Matsopoulos, Lambros Vlahos.   

Abstract

AIM: To evaluate the cytoprotective effect of amifostine against radiation-induced acute toxicity to the rectal mucosa. PATIENTS AND METHODS: 36 patients irradiated for prostate or gynecologic cancer were randomized to receive amifostine (n = 18, group A) or not (n = 18, group B). The radiation-induced acute rectal toxicity was evaluated by using three different toxicity scales: WHO scale, EORTC/RTOG toxicity criteria, and a modified toxicity scale based on the LENT-SOMA grading scale and the endoscopic terminology of the World Organization for Digestive Endoscopy. The objective measurements were coming from flexible rectosigmoidoscopy performed at baseline and 1-2 days after completion of the radiotherapy schedule. Anterior-posterior fields were used in the gynecologic patients while 3-D conformal 4-field technique was applied in the prostate cancer patients. The area under the curve (AUC) for dose-volume histograms (DVHs) of the rectum was also assessed during a 3-D treatment planning schedule, and no significant differences were assessed between the two groups, indicating a homogeneous dose-volume effect.
RESULTS: Amifostine was well tolerated. No grade 2 or higher WHO and EORTC/RTOG acute toxicity was noted in group A, while acute rectal toxicity (> or = grade 1) was observed in 16/18 patients of group B versus 2/18 of group A (p < 0.001). The onset as well as the duration of acute rectal toxicity were significantly improved in group A (p = 0.002). Rectosigmoidoscopy revealed more severe rectal mucositis in noncytoprotected patients (group B), and modified LENT-SOMA overall mucositis grading score was significantly lower in group A (p = 0.003).
CONCLUSION: Amifostine seems to have a significant cytoprotective efficacy in acute radiation-induced rectal mucositis in terms of symptomatic and objective endpoints.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627259     DOI: 10.1007/s00066-003-0970-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  13 in total

Review 1.  Prevention of pelvic radiation disease.

Authors:  Lorenzo Fuccio; Leonardo Frazzoni; Alessandra Guido
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-02-06

2.  The influence of craniofacial growth in a case of transverse facial cleft.

Authors:  Antje Kirbschus; Dietmar Gesch; Wolfram Kaduk; Tomasz Gedrange
Journal:  J Orofac Orthop       Date:  2006-05       Impact factor: 1.938

3.  Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial.

Authors:  A Razzaghdoust; H Mozdarani; B Mofid
Journal:  Strahlenther Onkol       Date:  2014-03-12       Impact factor: 3.621

4.  The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis.

Authors:  Eun Hee Seo; Tae Oh Kim; Tae Gyoon Kim; Hee Rin Joo; Jongha Park; Seung Ha Park; Sung Yeon Yang; Young Soo Moon; Min Jae Park; Dong Yup Ryu; Geun Am Song
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 5.  Amifostine in the management of radiation-induced and chemo-induced mucositis.

Authors:  Rene-Jean Bensadoun; Mark M Schubert; Rajesh V Lalla; Dorothy Keefe
Journal:  Support Care Cancer       Date:  2006-04-04       Impact factor: 3.603

6.  Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.

Authors:  Konstantinos H Katsanos; Evangelos Briasoulis; Pericles Tsekeris; Anna Batistatou; Maria Bai; Christos Tolis; Antonio Capizzello; Ioannis Panelos; Vasileios Karavasilis; Dimitrios Christodoulou; Epameinondas V Tsianos
Journal:  J Exp Clin Cancer Res       Date:  2010-06-10

7.  The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study.

Authors:  Fazilet Oner Dinçbaş; Didem Colpan Oksüz; Banu Atalar; Tuncay Altug; Sennur Ilvan; Nursal Gedik; Sevda Ozel; Sedat Koca
Journal:  Med Oncol       Date:  2008-11-30       Impact factor: 3.064

8.  Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy.

Authors:  Guang-hui Li; Dong-lin Wang; Yi-de Hu; Ping Pu; De-zhi Li; Wei-dong Wang; Bo Zhu; Ping Hao; Jun Wang; Xian-qiong Xu; Jiu-qing Wan; Yi-bing Zhou; Zheng-tang Chen
Journal:  Med Oncol       Date:  2009-09-16       Impact factor: 3.064

9.  Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study.

Authors:  Tereza Kertesz; Markus K A Herrmann; Antonia Zapf; Hans Christiansen; Robert M Hermann; Olivier Pradier; Heinz Schmidberger; Clemens F Hess; Andrea Hille
Journal:  Strahlenther Onkol       Date:  2009-09-12       Impact factor: 3.621

10.  Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma.

Authors:  Vassilis Kouloulias; Theodoros Kalogeropoulos; Kalliopi Platoni; John Georgakopoulos; George Matsopoulos; Dimitris Chaldeopoulos; Ivelina Beli; Panagiotis Pantelakos; Charalambos Asimakopoulos; John Kouvaris; Nikolaos Kelekis
Journal:  Radiat Oncol       Date:  2013-04-08       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.